DNAY
Income statement / Annual
Last year (2022), Codex DNA, Inc.'s total revenue was $27.44 M,
an increase of 148.44% from the previous year.
In 2022, Codex DNA, Inc.'s net income was -$48.42 M.
See Codex DNA, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$27.44 M
|
$11.04 M
|
$6.58 M
|
| Cost of Revenue |
$11.84 M |
$6.74 M |
$2.95 M |
| Gross Profit |
$15.60 M |
$4.30 M |
$3.63 M |
| Gross Profit Ratio |
0.57 |
0.39 |
0.55 |
| Research and Development
Expenses |
$23.46 M
|
$14.55 M
|
$8.93 M
|
| General & Administrative
Expenses |
$22.13 M
|
$14.23 M
|
$4.13 M
|
| Selling & Marketing
Expenses |
$16.49 M
|
$10.90 M
|
$6.93 M
|
| Selling, General &
Administrative Expenses |
$38.62 M
|
$25.13 M
|
$11.06 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$62.08 M |
$39.67 M |
$19.99 M |
| Cost And Expenses |
$73.92 M |
$46.42 M |
$22.94 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
-$1.22 M |
-$1.37 M |
$690,000.00 |
| Depreciation &
Amortization |
$3.23 M
|
$908,000.00
|
$1.46 M
|
| EBITDA |
-$46.49 M
|
-$39.41 M
|
-$15.86 M
|
| EBITDA Ratio |
-1.69 |
-3.57 |
-2.41 |
| Operating Income Ratio
|
-1.81
|
-3.65
|
-2.49
|
| Total Other
Income/Expenses Net |
-$1.96 M
|
-$3.57 M
|
-$1.64 M
|
| Income Before Tax |
-$48.45 M |
-$38.94 M |
-$18.01 M |
| Income Before Tax Ratio
|
-1.77
|
-3.53
|
-2.74
|
| Income Tax Expense |
-$24,000.00 |
$14,000.00 |
$5,000.00 |
| Net Income |
-$48.42 M |
-$38.96 M |
-$18.01 M |
| Net Income Ratio |
-1.77 |
-3.53 |
-2.74 |
| EPS |
-1.64 |
-1.83 |
-0.84 |
| EPS Diluted |
-1.64 |
-1.83 |
-0.84 |
| Weighted Average Shares
Out |
$29.46 M
|
$21.32 M
|
$21.32 M
|
| Weighted Average Shares
Out Diluted |
$29.46 M
|
$21.32 M
|
$21.32 M
|
| Link |
|
|
|
